Strongbridge Biopharma plc (NASDAQ: SBBP) is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses.
River Vision Development Corporation researches and develops protein therapies. The Company provides its products for the treatment of graves' orbitopathy.
Passage Bio is a genetic medicines company developing therapies for the treatment of rare monogenic central nervous system diseases
Nora Therapeutics is a specialty biopharmaceutical company developing therapeutics to address clinical unmet needs in reproductive medicine.
Nexcida, a Frazier Healthcare Partners portfolio company, is developing novel antibiotics to treat serious, life-threatening bacterial infections.
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases.
A technology-driven healthcare services company, Medley Health is committed to redefining the doctor-patient relationship in order to achieve high quality, cost-effective primary and preventative health care.
Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everythingwe do, from early research to product development
